Chronic lymphocytic leukemia: treatment of relapse

Abstract

Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia

“…Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia with >3000 new cases in the UK annually. 1 Its variable clinical course ranges from stable indolent disease that does not require treatment, to rapidly progressive disease that necessitates immediate therapeutic intervention. 2 Clinical response rates to current therapies are strongly influenced by genetic changes including disruption of DNA damage response (DDR) genes ATM and p53.…”